Psoriatic Arthritis | Emerging Therapies | Xeljanz (tofacitinib) | US | Wave 3 | 2019
Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA) and the only other oral targeted therapy besides Celgene’s PDE-4 inhibitor, Otezla, approved for this indication. In recent years, multiple new therapies have been approved for the treatment of PsA. However, Xeljanz’s unique MOA, oral administration, and strong efficacy warrant the attention of both rheumatologists and dermatologists. The Emerging Therapy series in psoriatic arthritis includes three waves that will track the awareness, trial, and usage of Xeljanz since its approval in December 2017 for the treatment of PsA. In addition, the series will examine physician-anticipated future trends in PsA treatment, particularly Xeljanz’s uptake, as well as assess Pfizer’s promotional efforts.
QUESTIONS ANSWERED
- What is the awareness of, familiarity with, and perceptions related to Xeljanz among U.S. rheumatologists and dermatologists?
- Among prescribers, for which patients are they prescribing Xeljanz, what are the reasons for prescribing, and how satisfied are they with Xeljanz?
- How do prescribers and nonprescribers compare across key metrics?
- How is the trial and adoption of Xeljanz tracking compared to other recent product launches in the autoimmune market?
PRODUCT DESCRIPTION
Emerging Therapies captures U.S. physicians’ awareness, perceptions, and usage of the launched product at one, six, and twelve months postlaunch, as well as the current and future impact on competitor therapies and the overall market. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, benchmarking against other launched agents, along with statistical comparative analysis with prior waves so that marketers can track and optimize the effectiveness of their launch strategy or fine-tune their product positioning to counter its impact on their brand’s share.
